Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Author(s):
Schoffski, P.; Wozniak, A.; Kasper, B.; Aamdal, S.; Leahy, M.G.; Rutkowski, P.; Bauer, S.; Gelderblom, H.; Italiano, A.; Lindner, L.H.; Hennig, I.; Strauss, S.; Zakotnik, B.; Anthoney, A.; Albiges, L.; Blay, J.Y.; Reichardt, P.; Sufliarsky, J.; Graaf, W.T.A. van der; Debiec-Rychter, M.; Sciot, R.; Cann, T. van; Marreaud, S.; Raveloarivahy, T.; Collette, S.; Stacchiotti, S.
Published
2018
Publication type
Article / Letter to editor
alveolar soft part sarcomaASPStranscription factor E3 (TFE3) gene rearrangementMET expressionMET tyrosine kinase inhibitorcrizotinib
Date issued
2018-03-31
Language
English
Is part of
Annals of Oncology (2018), Vol. 29, no. 3, p. 758-765
hdl
1887/96262
doi
10.1093/annonc/mdx774